AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01289912
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast.
Trial: NCT01289912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast.
Trial: NCT00092131
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet administered orally as a single witnessed dose before exercise challenge
Trial: NCT03835533
Drug: NKTR-214 (Cohort A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKTR-214 will be administered intravenously every 3 weeks for up to 2 years
Trial: NCT03348254
Drug: Single shot antibiotic prophylaxis
RxNorm normalized name: ChoreMate One-Shot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single shot preoperative antibiotic prophylaxis
Trial: NCT03348254
Drug: Multiple shot antibiotic prophylaxis
RxNorm normalized name: ChoreMate One-Shot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple shot perioperative antibiotic prophylaxis
Trial: NCT02372409
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01383538
Drug: FOLFIRINOX, IPI-926
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin: intravenous, 50 to 85 mg/m2, over 2 hrs, once per cycle.~Leucovorin: intravenous, 400 mg/m2, over 2 hrs, once per cycle.~Irinotecan: intravenous, 120 to 180 mg/m2, over 90 minutes, once per cycle.~5-FU: intravenous, 1600 to 2400mg/m2, over 46hr continuous infusion, once per cycle.~IPI-926: oral, 130 to 160 mg/day, daily, 14 days per cycle.
Trial: NCT01660763
Drug: Sufentanil NanoTab PCA System/15 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
Trial: NCT01660763
Drug: Placebo Sufentanil NanoTab PCA System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
Trial: NCT00078559
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
Trial: NCT01813240
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01813240
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01024322
Drug: Ciprofloxicine or Vigamox or other.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxicine or Vigamox or other to be used qid till epithelialized.
Trial: NCT01024322
Drug: Steroid (FML, Pred Forte, Flarex, etc.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid (FML, Pred Forte, Flarex, etc.) to be used qid for 8 weeks.
Trial: NCT04223193
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
Trial: NCT01311102
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.33cc normal saline
Trial: NCT02276300
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment of mild Endoxan application three days before Her2 vaccination
Trial: NCT04377646
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mg per day up to 2 months
Trial: NCT04377646
Drug: Zinc (Placebo)
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 pill per day up to 2 months
Trial: NCT01011010
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure.
Trial: NCT02182193
Drug: BIBF 1120 drinking solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00768274
Drug: RVX000222
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RVX000222 twice daily (b.i.d.) for 28 days
Trial: NCT00768274
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily (b.i.d.) for 28 days
Trial: NCT02446561
Drug: MRXXX
RxNorm normalized name: I'm afraid I don't have enough information to determine the full generic name for the drug abbreviation 'MRXXX'. Drug abbreviations can vary and may not be standardized, so without more context about the specific drug or clinical trial, I cannot provide the full generic name. If you have additional details about the drug or trial, please provide that information, and I'll do my best to look up the full generic name.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02446561
Drug: MR1XXX
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02446561
Drug: MR2XXX
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02446561
Drug: MR3XXX
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02142049
Drug: DA-EPOCH-R
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
Trial: NCT00864448
Drug: Atlace® 10 mg capsules, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fasting conditions
Trial: NCT00778674
Drug: Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00149253
Drug: a single-dose of Etoricoxib before induction of anesthesia
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04706468
Drug: TG-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules taken orally
Trial: NCT02491008
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects \<50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is \<0.4 mU/L, dose will be reduced by 25 mcg; TSH \>=0.4 and \<4.6 mU/L, no change to dose; TSH \>=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
Trial: NCT02491008
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
Trial: NCT00424528
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation solution and placebo inhalation powder
Trial: NCT01159626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single dose as matching placebo
Trial: NCT01757756
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo administered twice daily for 14 days
Trial: NCT03466333
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be encapsulated; participants will take the drug once a day for 6 months following delivery. It will be identical in appearance to the IMP.
Trial: NCT01512225
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet 10 mg orally three times daily for 14 days
Trial: NCT00360308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01126593
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group will receive the same subacromial infusion catheter however, the reservoir will be filled with 200cc of 0.9% Normal Saline.
Trial: NCT03830034
Drug: Amino Acid chelated iron tab 15 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) a dose recommended by the company of the product.~Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins \& milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline \& then 4, 8 \& 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed.
Trial: NCT01227681
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Chloride (NaCl) 0.9 %
Trial: NCT01091324
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg , tid
Trial: NCT03398005
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 1 g capsules administered orally once a day for 26 weeks
Trial: NCT00152776
Drug: ovaria comp 10 globuli 3 times per day 24 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: order of intervention and placebo varies between Groups I-III
Trial: NCT01569516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0mg, tid
Trial: NCT04255160
Drug: Estradiol (mylan or vivelle dot patch)
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (0.1mg/day patch) will be used by women for 7 days. Administration of the patch will follow the package guidelines to change the patch after 3-4 days of use.
Trial: NCT02575092
Drug: Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension)
RxNorm normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02575092
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02508311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo tablets twice daily for 16 weeks.
Trial: NCT00849251
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT00849251
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01906294
Drug: antidiabetic treatment (ATC A10B)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01850680
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Trial: NCT01850680
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:capsule Route of administration: oral
Trial: NCT01850680
Drug: folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:tablet Route of administration: oral
Trial: NCT02702518
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug vehicle 4 times a day for 8 weeks
Trial: NCT01512862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
Trial: NCT00868439
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02347761
Drug: Placebo BID eFlow Closed System (CS) nebulizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily (BID) eFlow Closed System (CS) nebulizer
Trial: NCT00001430
Drug: EPOCH II
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02995772
Drug: Aromatase Inhibitors (Arimidex)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of efficacy with chemotherapy
Trial: NCT02995772
Drug: Aromatase Inhibitors (Femara)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of efficacy with chemotherapy
Trial: NCT02995772
Drug: Aromatase Inhibitors (Aromasin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of efficacy with chemotherapy
Trial: NCT04301336
Drug: Vit D
RxNorm normalized name: Tri-Vit Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 patients from each participating hospital that will receive Vit-D medication (1500 IU to 3500 IU ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.
Trial: NCT04301336
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 patients from each participating hospital that will receive Zinc supplements (15 mg to 50 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.
Trial: NCT04301336
Drug: Statins (Cardiovascular Agents)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 patients from each participating hospital that will receive Simvastatin orally (20 mg to 40 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.
Trial: NCT04301336
Drug: Folic Acid Supplementation
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid dose of 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response
Trial: NCT01670656
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)
Trial: NCT03986008
Drug: Benaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment of Benaglutide lasted three months.During the first week: 0.1mg per day;During the second week: 0.14mg per day; From third week onwards, 0.2mg per day.
Trial: NCT01715805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-matched placebo capsule once per day
Trial: NCT01715805
Drug: Antidepressant Therapy (ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.
Trial: NCT02904304
Drug: Desloratadine+Phenylephrine+Ibuprofen
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 01 tablet, orally, every 12 hours.
Trial: NCT02904304
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 01 tablet, orally, every 12 hours.
Trial: NCT03315000
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same as placebo arm description
Trial: NCT01049425
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 cycles, intravenous infusion, day 1 every three weeks
Trial: NCT01049425
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 cycles, intravenous infusion, day 1 every 3 weeks
Trial: NCT00385931
Drug: Valsartan and simvastatin
RxNorm normalized name: simvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03199625
Drug: SSRI antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02324933
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl Patient Controlled Analgesia for post-operative pain management
Trial: NCT00137033
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00137033
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02741960
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg placebo three times daily
Trial: NCT03332524
Drug: SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 Ibuprofen and capsules Chlorpheniramine maleate 3 time per day for 72 hours
Trial: NCT03332524
Drug: 2 capsules Ibuprofen and 1 placebo
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen and placebo
Trial: NCT00637221
Drug: NPL-2009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of either 50mg, 100 mg or 150 mg NPL-2009
Trial: NCT03104634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and delivery device matched to active intervention
Trial: NCT01558622
Drug: dexketoprofen trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg intravenous infusion
Trial: NCT01558622
Drug: dexketoprofen trometamol + tramadol hydrochloride
RxNorm normalized name: dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion of 50mg dexketoprofen trometamol + 100mg tramadol hydrochloride
Trial: NCT01558622
Drug: dexketoprofen trometamol + pethidine hydrochloride
RxNorm normalized name: dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion of 50mg dexketoprofen trometamol + 50mg pethidine hydrochloride
Trial: NCT02512575
Drug: AZD9567 Monohydrat
RxNorm normalized name: Lactose Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9567 oral suspension 0.5 to 10 mg/ml
Trial: NCT02512575
Drug: Placebo oral suspension/ Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02512575
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 60mg oral capsules (12 capsules of 5 mg each).
Trial: NCT03152552
Drug: LIK066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIK066 was supplied in different doses as tablets taken orally.
Trial: NCT03152552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied as tablets and capsules taken orally.
Trial: NCT00160433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral Daily for 12 weeks
Trial: NCT00758953
Drug: Placebo Once Weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semi-solid
Trial: NCT00758953
Drug: Placebo Twice Weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semi-solid
Trial: NCT02983734
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill
Trial: NCT01517698
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to RO4917523 orally once a day for 12 weeks
Trial: NCT01517698
Drug: RO4917523 0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg orally once a day for 12 weeks
Trial: NCT01517698
Drug: RO4917523 1.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg orally once a day for 12 weeks
Trial: NCT03151434
Drug: US Guided Paravertebral Catheter (0.2% ropivicaine bolus)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.